• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do Artificially Sweetened Drinks Increase Risk for Stroke?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Mossavar-Rahman et al. (Stroke, 2019) sought to assess whether there is an association between artificially sweetened beverages (ASB) and risk of stroke, coronary heart disease, and all-cause mortality

METHODS:

  • Multicenter longitudinal cohort study
    • Women’s Health Initiative Observational Study (WHI-OS)
    • 100,000 postmenopausal women enrolled (1993-1998)
    • Women were aged 50 to 79 years
    • 11.9 years mean follow up in parent study
  • In the current study, participants were asked about their ABS consumption at the 3-year time point
  • Outcomes
    • Overall stroke
    • Coronary heart disease (CHD)
    • All-cause mortality
  • Exposure
    • Questionnaire that asked about the drinking frequency of unsweetened beverages during the previous 3 months
    • 4 categories: <1 time a week | 1 to 4 times a week | 5 to 7 times a week | ≥2 times a day
  • Multivariate analyses to control for confounding

RESULTS:

  • 81,714 women were included
    • 64.1% of women were infrequent consumers (never or <1/week) of ASB
    • 5.1% consuming ≥2 ASBs/day
  • Those consuming ≥2 ASBs/day (most frequent) compared to <1 ASBs/week (rare or none)
    • Had significantly greater likelihood of all end points (except hemorrhagic stroke)
  • Adjusted models demonstrated the following
    • All stroke:  Hazard ratio (HR) 1.23 (95% CI, 1.02–1.47)
    • Ischemic stroke: HR 1.31 (95% CI, 1.06–1.63) 
    • CHD: HR 1.29 (95% CI, 1.11–1.51)
    • All-cause mortality: HR 1.16 (95% CI, 1.07–1.26)
  • No prior history of CVD or diabetes
    • High consumption was associated with >2-fold increased risk of small artery occlusion ischemic stroke
    • HR 2.44 (95% CI, 1.47–4.04)
  • BMI ≥30
    • No significant interaction between BMI across most of the various frequency categories
    • High consumption (5-7 ASBs/week) was associated with increased risk of ischemic stroke (P=0.05)
      • HR 2.03 (95% CI, 1.38–2.98)

CONCLUSION:

  • In postmenopausal women, higher intake of ABS was associated with increased risk for ischemic stroke, CHD, and all-cause mortality
  • Authors recognize limitation of study due to observational design and that further studies would be required to guide clinical recommendations

Learn More – Primary Sources:

Artificially Sweetened Beverages and Stroke, Coronary Heart Disease, and All-Cause Mortality in the Women’s Health Initiative

JAMA: No Compelling Evidence of Health Benefits From Nonsugar Sweeteners


Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is the DASH Diet Effective for Obese Women with PCOS?
Does the Mediterranean Diet Decrease Risk of Breast Cancer?
From Genetics to Soybeans: What are the Risk Factors for Uterine Fibroids?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site